Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for the adjunctive or monotherapy treatment of major depressive disorder in adults. The company was founded in 2004 and is headquartered in Coral Gables, Florida.

Relmada Therapeutics, Inc.

Relmada Therapeutics is dedicated to improving the standard of care for central nervous system (CNS) disorders. The company focuses on advancing its ongoing Phase 3 program of REL-1017, which aims to offer a treatment for major depressive disorder (MDD).

COM:RELMADA